Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Cost-of-illness study for non-small-cell lung cancer using real-world data.

Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK.

Curr Oncol. 2019 Apr;26(2):102-107. doi: 10.3747/co.26.4555. Epub 2019 Apr 1.

2.

How equitable is access to treatment for lung cancer patients? A population-based review of treatment practices in Ontario.

Evans WK, Stiff J, Woltman KJ, Ung YC, Su-Myat S, Manivong P, Tsang K, Nazen-Rad N, Gatto A, Tyrrell A, Anas R, Darling G, Sawka C.

Lung Cancer Manag. 2017 Dec;6(3):77-86. doi: 10.2217/lmt-2017-0013. Epub 2017 Dec 1.

3.

Sociodemographic characteristics associated with thyroid cancer risk in Canada.

Bushnik T, Evans WK.

Health Rep. 2018 Oct 17;29(10):3-11.

4.

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, Garner R, Miller AB, Evans WK, Popadiuk CM, Wolfson M, Coldman AJ.

Curr Oncol. 2017 Dec;24(6):401-406. doi: 10.3747/co.24.3850. Epub 2017 Dec 20.

5.

Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

Cheung MC, Chan KK, Sabharwal M, Fields A, Chambers A, Evans WK.

ESMO Open. 2017 Feb 22;1(6):e000124. doi: 10.1136/esmoopen-2016-000124. eCollection 2016. Review.

6.

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, Liu G, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Nasute Fauerbach PV, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart L, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrowes P, MacEachern P, Urbanski S, Sin DD, Tan WC, Leighl NB, Shepherd FA, Evans WK, Tsao MS, Lam S; PanCan Study Team.

Lancet Oncol. 2017 Nov;18(11):1523-1531. doi: 10.1016/S1470-2045(17)30597-1. Epub 2017 Oct 18.

PMID:
29055736
7.

Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals.

Evans WK, de Oliveira C.

J Thorac Oncol. 2017 Oct;12(10):1461-1463. doi: 10.1016/j.jtho.2017.08.013. No abstract available.

8.

Lessons learned implementing a province-wide smoking cessation initiative in Ontario's cancer centres.

Evans WK, Truscott R, Cameron E, Peter A, Reid R, Selby P, Smith P, Hey A.

Curr Oncol. 2017 Jun;24(3):e185-e190. doi: 10.3747/co.23.3506. Epub 2017 Jun 27.

9.

Measuring value and benefit-a matter of perspective.

Evans WK, Cheung MC, Chan KK.

Lancet Oncol. 2017 Jul;18(7):839-840. doi: 10.1016/S1470-2045(17)30423-0. Epub 2017 Jun 2. No abstract available.

PMID:
28583795
10.

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.

Cressman S, Peacock SJ, Tammemägi MC, Evans WK, Leighl NB, Goffin JR, Tremblay A, Liu G, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Mayo JR, Yee J, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrowes P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, Lam S.

J Thorac Oncol. 2017 Aug;12(8):1210-1222. doi: 10.1016/j.jtho.2017.04.021. Epub 2017 May 10.

11.

Engaging specialist oncologists in the assessment of oncology drugs in Canada.

Evans WK, Sabharwal M, Fields A, Chan KKW, Cheung M, Chambers A.

Lancet Oncol. 2017 May;18(5):573-575. doi: 10.1016/S1470-2045(17)30266-8. No abstract available.

PMID:
28495278
12.
13.

Using Data From Ontario's Episode-Based Funding Model to Assess Quality of Chemotherapy.

Kaizer L, Simanovski V, Lalonde C, Tariq H, Blais I, Evans WK.

J Oncol Pract. 2016 Oct;12(10):e870-e877.

PMID:
27858565
14.

Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK.

Lung Cancer. 2016 Nov;101:98-103. doi: 10.1016/j.lungcan.2016.09.013. Epub 2016 Sep 28.

PMID:
27794416
15.

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Evans WK, Flanagan WM, Miller AB, Goffin JR, Memon S, Fitzgerald N, Wolfson MC.

Curr Oncol. 2016 Jun;23(3):e179-87. doi: 10.3747/co.23.2988. Epub 2016 Jun 9.

16.

Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses--Reply.

Goffin JR, Flanagan WM, Evans WK.

JAMA Oncol. 2016 Feb;2(2):278-9. doi: 10.1001/jamaoncol.2015.4462. No abstract available.

PMID:
26869003
17.

A population-based study of the epidemiology of pancreatic cancer: a brief report.

Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Goyert N, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC, Mittmann N.

Curr Oncol. 2015 Dec;22(6):e478-84. doi: 10.3747/co.22.2653.

18.

Cost-effectiveness of Lung Cancer Screening in Canada.

Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, Evans WK.

JAMA Oncol. 2015 Sep;1(6):807-13. doi: 10.1001/jamaoncol.2015.2472.

PMID:
26226181
19.

Performance of the cancer risk management model lung cancer screening module.

Flanagan WM, Evans WK, Fitzgerald NR, Goffin JR, Miller AB, Wolfson MC.

Health Rep. 2015 May;26(5):11-8.

20.

Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals.

Fitzgerald NR, Flanagan WM, Evans WK, Miller AB; Canadian Partnership against Cancer (CPAC) Cancer Risk Management (CRM) Lung Cancer Working.

Scand J Work Environ Health. 2015 Jul;41(4):407-12. doi: 10.5271/sjweh.3496. Epub 2015 Apr 3.

21.

Health system costs for stage-specific breast cancer: a population-based approach.

Mittmann N, Porter JM, Rangrej J, Seung SJ, Liu N, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC.

Curr Oncol. 2014 Dec;21(6):281-93. doi: 10.3747/co.21.2143.

22.

Population-based utilization of radiation therapy by a Canadian breast cancer cohort.

Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch JS, Evans WK, Leighl NB, Trudeau M, Earle CC.

Curr Oncol. 2014 Oct;21(5):e715-7. doi: 10.3747/co.21.2162.

23.

Implementing a regional oncology information system: approach and lessons learned.

Evans WK, Ashbury FD, Hogue GL, Smith A, Pun J.

Curr Oncol. 2014 Oct;21(5):224-33. doi: 10.3747/co.21.1923.

24.

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, Bolbocean C, Shepherd FA, Tsao MS, Manos D, Liu G, Atkar-Khattra S, Cromwell I, Johnston MR, Mayo JR, McWilliams A, Couture C, English JC, Goffin J, Hwang DM, Puksa S, Roberts H, Tremblay A, MacEachern P, Burrowes P, Bhatia R, Finley RJ, Goss GD, Nicholas G, Seely JM, Sekhon HS, Yee J, Amjadi K, Cutz JC, Ionescu DN, Yasufuku K, Martel S, Soghrati K, Sin DD, Tan WC, Urbanski S, Xu Z, Peacock SJ; Pan-Canadian Early Detection of Lung Cancer Study Team.

J Thorac Oncol. 2014 Oct;9(10):1449-58. doi: 10.1097/JTO.0000000000000283.

25.

Utilization and costs of home care for patients with colorectal cancer: a population-based study.

Mittmann N, Liu N, Porter J, Seung SJ; Hon, Isogai PK, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, Earle CC.

CMAJ Open. 2014 Feb 4;2(1):E11-7. doi: 10.9778/cmajo.20130026. eCollection 2014 Jan.

26.

End-of-life home care utilization and costs in patients with advanced colorectal cancer.

Mittmann N, Liu N, Porter JM, Isogai PK, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC.

J Community Support Oncol. 2014 Mar;12(3):92-8.

PMID:
24971414
27.

International efforts in health care reform: systemic treatment funding model reform in Ontario.

Kaizer L, Simanovski V, Blais I, Lalonde C, Evans WK.

J Oncol Pract. 2014 May;10(3):190-2. doi: 10.1200/JOP.2014.001389. No abstract available.

PMID:
24839279
28.

A mixed methods approach to understand variation in lung cancer practice and the role of guidelines.

Brouwers MC, Makarski J, Garcia K, Akram S, Darling GE, Ellis PM, Evans WK, Giacomini M, Martelli-Reid L, Ung YC.

Implement Sci. 2014 Mar 22;9(1):36. doi: 10.1186/1748-5908-9-36.

29.

Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.

You JJ, Wong RK, Darling G, Gulenchyn K, Urbain JL, Evans WK.

J Thorac Oncol. 2013 Dec;8(12):1563-9. doi: 10.1097/JTO.0000000000000006.

30.

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).

Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK.

Lung Cancer. 2013 Oct;82(1):115-20. doi: 10.1016/j.lungcan.2013.07.012. Epub 2013 Aug 17.

PMID:
23962449
31.

Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative.

Evans WK, Ung YC, Assouad N, Chyjek A, Sawka C.

J Thorac Oncol. 2013 Jul;8(7):876-82. doi: 10.1097/JTO.0b013e31828cb548.

32.

Prognostic implications of treatment delays in the surgical resection of lung cancer.

Evans WK.

Thorac Surg Clin. 2013 May;23(2):225-32. doi: 10.1016/j.thorsurg.2013.01.006. Epub 2013 Feb 8. Review.

PMID:
23566974
33.

Canadian Cancer Risk Management Model: evaluation of cancer control.

Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, Mittmann N, Fairclough L, Oderkirk J, Finès P, Gribble S, Hoch J, Hicks C, Omariba DW, Ng E.

Int J Technol Assess Health Care. 2013 Apr;29(2):131-9. doi: 10.1017/S0266462313000044. Epub 2013 Mar 20.

PMID:
23514623
34.

Population-based home care services in breast cancer: utilization and costs.

Mittmann N, Isogai PK, Saskin R, Liu N, Porter JM, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC.

Curr Oncol. 2012 Dec;19(6):e383-91. doi: 10.3747/co.19.1078.

35.

Raising the bar: using program evaluation for quality improvement.

Anas R, Stiff J, Speller B, Foster N, Bell R, McLaughlin V, Evans WK.

Healthc Manage Forum. 2013 Winter;26(4):191-5.

PMID:
24696943
36.

The school nurse role in preparing for sudden cardiac arrest in the school setting.

Evans WK, Ficca M.

J Sch Nurs. 2012 Dec;28(6):418-22. doi: 10.1177/1059840512451743. Epub 2012 Jun 25.

PMID:
22733830
37.

Guidelines for health technologies: specific guidance for oncology products in Canada.

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl NB, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Taylor SC, Jacobs P, Oh PI.

Value Health. 2012 May;15(3):580-5. doi: 10.1016/j.jval.2011.12.006. Epub 2012 Feb 16.

38.

Variation and consternation: access to unfunded cancer drugs in Canada.

Berry SR, Evans WK, Strevel EL, Bell CM.

J Oncol Pract. 2012 Jan;8(1):35-9. doi: 10.1200/JOP.2011.000278.

39.

In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.

Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer JA, Evans WK, Strevel EL, Neumann PJ.

Health Aff (Millwood). 2012 Apr;31(4):709-17. doi: 10.1377/hlthaff.2011.0251.

40.

Computed tomography screening for lung cancer without a smoking cessation program--not a cost-effective idea.

Evans WK, Wolfson MC.

J Thorac Oncol. 2011 Nov;6(11):1781-3. doi: 10.1097/JTO.0b013e3182344007. No abstract available.

41.

Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.

Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu CS, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.

J Thorac Oncol. 2011 Aug;6(8):1367-72. doi: 10.1097/JTO.0b013e318220c912. Erratum in: J Thorac Oncol. 2012 Mar;7(3):628.

42.

Selecting patients with extensive-stage small cell lung cancer for prophylactic cranial irradiation by predicting brain metastases.

Greenspoon JN, Evans WK, Cai W, Wright JR.

J Thorac Oncol. 2011 Apr;6(4):808-12. doi: 10.1097/JTO.0b013e31820d782d.

43.

Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.

Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, Neumann PJ.

J Clin Oncol. 2010 Sep 20;28(27):4149-53. doi: 10.1200/JCO.2010.29.1625. Epub 2010 Aug 9.

PMID:
20697077
44.

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ.

J Natl Cancer Inst. 2010 Jun 16;102(12):859-65. doi: 10.1093/jnci/djq179. Epub 2010 May 26.

45.

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis.

J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.

PMID:
20160168
46.

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.

Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

J Thorac Oncol. 2010 Feb;5(2):260-74. doi: 10.1097/JTO.0b013e3181c6f035. Review.

47.

Cancer diagnostic assessment programs: standards for the organization of care in Ontario.

Brouwers M, Oliver TK, Crawford J, Ellison P, Evans WK, Gagliardi A, Lacourciere J, Lo D, Mai V, McNair S, Minuk T, Rabeneck L, Rand C, Ross J, Smylie J, Srigley J, Stern H, Trudeau M.

Curr Oncol. 2009 Dec;16(6):29-41.

48.

Evidence-based approach to the introduction of positron emission tomography in ontario, Canada.

Evans WK, Laupacis A, Gulenchyn KY, Levin L, Levine M.

J Clin Oncol. 2009 Nov 20;27(33):5607-13. doi: 10.1200/JCO.2009.22.1614. Epub 2009 Oct 26. Review.

PMID:
19858395
49.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group.

J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.

PMID:
19666851
50.

Positron emission tomography in staging early lung cancer: a randomized trial.

Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN.

Ann Intern Med. 2009 Aug 18;151(4):221-8, W-48. Epub 2009 Jul 6.

PMID:
19581636

Supplemental Content

Loading ...
Support Center